Home › Compare › MVES vs JNJ

MVES vs JNJ: Dividend Comparison 2026

MVES yields 97560.98% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVES wins by $3.776305572355012e+26M in total portfolio value
10 years
MVES
MVES
● Live price
97560.98%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.776305572355012e+26M
Annual income
$376,870,661,561,253,050,000,000,000,000,000.00
Full MVES calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — MVES vs JNJ

📍 MVES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVESJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVES + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MVES pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVES
Annual income on $10K today (after 15% tax)
$8,292,682.93/yr
After 10yr DRIP, annual income (after tax)
$320,340,062,327,065,100,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, MVES beats the other by $320,340,062,327,065,100,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVES + JNJ for your $10,000?

MVES: 50%JNJ: 50%
100% JNJ50/50100% MVES
Portfolio after 10yr
$1.888152786177506e+26M
Annual income
$188,435,330,780,626,520,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MVES
No analyst data
Altman Z
-1478.2
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVES buys
0
JNJ buys
0
No recent congressional trades found for MVES or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVESJNJ
Forward yield97560.98% ✓3.36%
Annual dividend / share$2.00$4.96 ✓
Payout ratio50% ✓55%
1-year div growth0%4.2% ✓
5-year div CAGR0%5.8% ✓
Portfolio after 10y$3.776305572355012e+26M$20.0K ✓
Annual income after 10y$376,870,661,561,253,050,000,000,000,000,000.00 ✓$827.78
Total dividends collected$3.775807569040114e+26M$5.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MVES vs JNJ ($10,000, DRIP)

YearMVES PortfolioMVES Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$9,766,798$9,756,097.56$10,676$355.77+$9.76M → MVES
2$8,915,668,218$8,905,217,744.22$11,407$389.39+$8915.66M → MVES
3$7,606,895,774,454$7,597,356,009,460.71$12,198$426.53+$7606895.76M → MVES
4$6,066,181,203,275,186$6,058,041,824,796,520.00$13,056$467.62+$6066181203.26M → MVES
5$4,521,476,760,610,756,600$4,514,985,946,723,252,000.00$13,987$513.12+$4521476760610.74M → MVES
6$3,149,960,361,765,127,000,000$3,145,122,381,631,274,000,000.00$14,998$563.56+$3149960361765127.00M → MVES
7$2,051,128,108,701,665,300,000,000$2,047,757,651,114,576,600,000,000.00$16,098$619.52+$2051128108701665280.00M → MVES
8$1,248,379,585,384,790,000,000,000,000$1,246,184,878,308,479,300,000,000,000.00$17,295$681.69+$1.24837958538479e+21M → MVES
9$710,182,873,129,118,200,000,000,000,000$708,847,106,972,756,500,000,000,000,000.00$18,599$750.82+$7.101828731291182e+23M → MVES
10$377,630,557,235,501,200,000,000,000,000,000$376,870,661,561,253,050,000,000,000,000,000.00$20,022$827.78+$3.776305572355012e+26M → MVES

MVES vs JNJ: Complete Analysis 2026

MVES — Stock

The Movie Studio, Inc. operates as a vertically integrated motion picture production and distribution company. It focuses on acquiring, developing, producing, and distributing independent motion picture content for consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales, and various media devices. The company is establishing its own OTT VOD platform to integrate its own and aggregated feature film projects, television programming, and other media intellectual properties. It is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution. The company was formerly known as Destination Television, Inc. and changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio, Inc. was incorporated in 1961 and is headquartered in Fort Lauderdale, Florida.

Full MVES Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this MVES vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVES vs SCHDMVES vs JEPIMVES vs OMVES vs KOMVES vs MAINMVES vs ABBVMVES vs MRKMVES vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.